In patients with advanced uveal melanoma, treatment with the agent selumetinib, compared with chemotherapy, resulted in an improved cancer progression-free survival time and tumor response rate, but no improvement in overall survival, according to a study.
http://ift.tt/1vSWvdJ
http://ift.tt/1vSWvdJ
No comments:
Post a Comment